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MicroRNAs (miRNA) play an important role in tumorigenesis, proliferation, and differentiation.
Altered miRNA expression in cancer indicates that miRNAs can function as tumor suppressors or
oncogenes. MiR-449c downregulation in non-small cell lung cancer (NSCLC) compared with normal
lung tissues was investigated in this study. NSCLC cell proliferation and invasion assays indicate that
transfection of miR-449c expression plasmid inhibits the proliferation and invasion ability of NCI-
H23 and NCI-H838 cells. In addition, miR-449c overexpression could suppress tumor growth
in vivo. Morever, c-Myc was identiﬁed as a direct target gene of miR-449c. These ﬁndings clearly sug-
gest that miR-449c downregulation and c-Myc ampliﬁcation may be involved in the development of
NSCLC.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the leading cause of cancer-related deaths world-
wide, with more than 1600000 new cases of lung cancer and more
than 1370000 attributable deaths each year [1]. Non-small cell
lung cancers (NSCLC) are the major types of lung cancer with
low 5 year survival rate. Although various therapeutic tools have
been developed, most patients have died because of insufﬁcient
speciﬁc biomarkers and tools for early screening and diagnosis
[2,3]. c-Myc is a multifunctional, nuclear phosphoprotein involved
in cell cycle progression and apoptosis. The deregulation expres-
sion of this gene has been associated with leukemia, breast cancer,
ovarian cancer, liver cancer, and NSCLC [4–8]. In acute myeloid leu-
kemia hematopoietic tumors, c-Myc overexpression promotes tu-
mor cell growth and proliferation. But the expression of c-Myc
was inhibited by miR-145, which induced by P53 [9].
MicroRNAs (miRNA) are endogenous noncoding RNAs of
approximately 22 nucleotides that regulate gene expression at
post-transcriptional level by binding to the complementary se-
quences within mRNAs [10,11]. Several miRNAs exhibit typical
expression proﬁles and are critical in human tumors. The dysregu-
lation of miRNAs and their target genes leads to various diseasesincluding cancers. Early studies have shown that miR-574-5p
was upregulated in colorectal cancer and inversely correlated with
the Qkis expression. MiR-574-5p inhibition suppressed the growth
of tumors in nude mice [12]. Notably, miR-21 is an oncogene in
various types of cancer [13–15]. In addition, miR-449c is a tumor
suppressor, with its expression induced by transcription factor
E2F1. Then the direct targets of miR-449c, CDK6 and CDC25A, lead
to the phosphorylation of E2F1 [16]. Although many studies have
proved the crucial roles of miRNAs in cancer, reports on miR-
449c in NSCLC remain limited.
In thepresent study,miR-449cwas found to bedownregulated in
NSCLC by miRNA speciﬁc q-PCR. MiR-449c overexpression in vitro
inhibited the proliferation and invasion of NSCLC cells. In vivo,
miR-449c could suppress tumor growth in nudemice. Furthermore,
luciferase reporter assay suggested thatmiR-449c directly targets c-
Myc and represses its expression. These results support the involve-
ment of miR-449c in NSCLC progression. This ﬁnding is advanta-
geous in achieving a deeper understanding of the anti-cancer
mechanism of miRNA and may provide a rationale for developing
miRNA-based strategies for the treatment of lung cancer.
2. Materials and methods
2.1. Cell lines and human tissues
Human lung cancer cell lines NCI-H23 and NCI-H838 were ob-
tained from the American Type Culture Collection. Both the cells
were maintained in RPMI 1640 (GIBCO, USA) containing 10% fetal
bovine serum (FBS) at 37 C in 5% CO2. Human NSCLC specimens
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(n = 12) were obtained from the First Afﬁliated Hospital of Zhengz-
hou University with documented informed consent in each case.
2.2. RNA extraction and real-time qRT-PCR
RNA from the tissues or cells was isolated using mirVana™miR-
NA Isolation Kit (Ambion, USA) following the manufacturer’s
instructions. RNA was used to validate the c-Myc and miRNA
expression. Real-time qRT-PCR was performed using miRNA-spe-
ciﬁc primers to analyze the miRNA expression. A mixture of 2 lg
of the fraction of small RNA was used in reverse transcription.
The cDNAs were then used to examine the miR-449c and U6
snRNA expression. The PCR reaction was conducted with speciﬁc
(miR-449c-F-q or U6-F) and general primers (Rev). To detect the
c-Myc level, 5 lg of the fraction of large RNA was used in the re-
verse transcription. c-Myc gene (468 bp) was ampliﬁed with spe-
ciﬁc paired primers (UTR-S and UTR-AS), and GAPDH was used
as the loading control. The expression level was quantiﬁed using
the 2DDCt method. Each experiment was performed in triplicate.
2.3. DNA construction
To construct miR-449c expression plasmid, a DNA fragment
containing miR-449c sequence was ampliﬁed from HEK293 cell
genome using speciﬁc primers (miR-449c-F and miR-449c-R).
The PCR products were then inserted into pcDNA3.1 by BamHI
and EcoRI. The fragment of c-Myc 30UTR containing the putative
target site of miR-449c (468 bp) was ampliﬁed from HEK293 cell
cDNA library by PCR. UTR-F and UTR-R were used as primers. c-
Myc 30UTR with mutated 30UTR (468 bp) was synthesized in BGI
(Beijing, China). These two DNA products were all inserted into
pmirGLO dual-luciferase reporter vector (Promega, Madison, WI,
USA) by PmeI and XhoI separately. c-Myc CDS DNA fragment
(1365 bp) was also ampliﬁed from the HEK293 cell cDNA library
using paired primers (CDS-F and CDS-R) and inserted into the
pcDNA3.1 expression plasmid by BamHI and EcoRI. All primers
listed in Table 1 were purchased from BGI (Beijing, China).
2.4. Cell viability assay
Cells were seeded in 96-well plate at a concentration of 103
cells/well and maintained at 37 C for 24, 48, and 72 h after trans-
fection. The cells were then treated with 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT; 0.5 mg/ml) for 4 h at
37 C. The absorbance at 570 nm was determined with a micro-
plate reader.
2.5. Colony formation assay
Cells were seeded in a six-well plate at a ﬁnal concentration of
2000 cells/well after transfection and maintained in RPMI 1640Table 1
Primers used in the experiments.
Primer name Primer sequences
U6-RT 50-GTCGTATCCAGTGC
U6-F 50-TGCGGGTGCTCGC
miR-449c-RT 50-GTCGTATCCAGTGC
miR-449c-F-q 50-TGCGGUAGGCAGU
Rev 50-CCAGTGCAGGGTC
miR-449c-F 50-CGCGGATCCTAATG
miR-449c-R 50-CCGGAATTCTGGG
UTR-F 50-GGGTTTAAACGGA
UTS-R 50-CCGCTCGAGTGGC
CDS-F 50-CGCGGATCCGACG
CDS-R 50-CCGGAATTCTTACG(GIBCO, USA) containing 10% FBS at 37 C in 5% CO2. After 9 d,
clones were ﬁxed with methanol and stained with 2% Giemsa solu-
tion (Merck, Germany).
2.6. Cell invasion assay
Cell invasion assay was performed using Transwell cell culture
inserts (Invitrogen, USA) coated with Matrigel. The bottom cham-
ber was ﬁlled with DMEM containing 10% FBS. Tumor cells
(1  105 cells in a total volume of 100 ll) seeded in the upper
chamber with DMEM containing 2% FBS were incubated at 37 C
in 5% CO2. The transfected cells were allowed to migrate for 8 h.
The passed cells were then stained with crystal violet solution
and photographed under a microscope.
2.7. Flow cytometry analysis
Apoptosis was also determined using the Annexin V-PE/7-ami-
no actinomycin D (7AAD) detection kit from BD Pharmingen (San
Diego, CA). After transfection, the cells were washed in cold PBS,
followed by Annexin V-PE and 7AAD staining, following the man-
ufacturer’s instructions. The cells were then analyzed by ﬂow
cytometry.
2.8. Luciferase reporter assays
Tumor cells were seeded in 24-well plates. After 24 h, the two
luciferase reporter plasmids were transfected separately or
cotransfected with miR-449c expression plasmid or its control vec-
tor using Lipofectamine 2000 (Invitrogen, USA). Fireﬂy and renilla
luciferase activities were measured 48 h post-transfection using
the Dual-Glo Luciferase Assay System (Promega, USA) and Varios-
kan Flash microplate reader (Thermo, USA). Fireﬂy luciferase was
normalized to renilla luciferase activity. All transfections were per-
formed thrice.
2.9. Western blot
Cell lysates (40 lg) were separated by 10% SDS–PAGE and
transferred onto polyvinylidene diﬂuoride membranes (Millipore,
USA). Membranes were blocked with TBS Tween-20 buffer con-
taining 5% milk, and then incubated with rabbit polyclonal anti-
body to c-Myc (Abcam, UK), P53 (Abcam, UK), AKT (CST, USA),
and GAPDH (abcam, UK). The membranes were then incubated
with goat anti-rabbit IgG-HRP secondary antibody (CST, USA).
The protein expression was assessed by enhanced chemilumines-
cence and exposure to the chemiluminescent ﬁlm.
2.10. Murine xenograft model
BABL/c nude mice (5 week old) were purchased from the Ani-
mal Center of the Chinese Academy of Science (Shanghai, China)AGGGTCCGAGGTGCACTGGATACGACAAAATATGG-30
TTCGGCAGC-30
AGGGTCCGAGGTGCACTGGATACGACACAGCCG-30
GUAUUGCUAGCG-30
CGAGGT-30
CAATCGTTTGCATCTG-30
TTTGGTCTTTCAAGGAG-30
AAAGTAAGGAAAACG-30
TCAATGATATATTTG-30
ATGCTGGATTTTTTTCGGGTAGTG-30
CACAAGAGTTCCGTAG-30
Fig. 1. MiR-449c is lowly expressed and inversely correlated with c-Myc in NSCLC specimens and cell lines. The expression levels of (A) miR-449c and (B) c-Myc mRNA were
measured in 12 pairs of NSCLC tissues, NCI-H23 and NCI-H838 cell lines by real-time qRT-PCR. U6 snRNA and GAPDH were used as loading control. MiR-449c and c-Myc
mRNA expression was determined by triplicate measurements for each sample and were quantiﬁed using the 2DDCt method. The miR-449c and c-Myc expression level in
normal tissues is set to 1. (C) Western blot was performed to analyze the c-Myc protein, and GAPDH was used as control. (D and E) The correlation of miR-449c/MYC mRNA
(D, r = 0.781) and miR-449c/MYC protein (E, r = 0.684) is shown. ⁄P < 0.05.
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The mice used in the experiments were conducted in accordance
with the National Institute of Health Guide for the Care on the
use of laboratory animals. A total of 1  107 cells stably expressing
miR-449c were injected subcutaneously into the nude mice. Cells
transfected with control vector were used as the control group.
The mice were killed 22 d after injection, and tumor sizes were
measured.
2.11. Statistical analysis
All data in the study were evaluated using SPSS 11.5 (SPSS Inc.,
USA). Student0s t-test or one-way ANOVA test was performed to
analyze the signiﬁcance of differences between sample means ob-
tained from three independent experiments. Differences were con-
sidered signiﬁcant at P values <0.05.
3. Results
3.1. MiR-449c is lowly expressed and inversely correlated with c-Myc
expression in NSCLC tissues
To analyze the correlation of miR-449c and c-Myc in NSCLC,
real-time qRT-PCR was performed to quantify the level ofmiR-449c and c-Myc in 12 pairs of matched human NSCLC tis-
sues/surrounding tissues and two NSCLC cell lines, NCI-H23 and
NCI-H838. Fig. 1A and B show a lower miR-449c expression,
whereas the c-Myc mRNA expression is higher in the NSCLC tissues
and cell lines than that in normal tissues. Furthermore, we investi-
gated the c-Myc protein level by Western blot analysis. The c-Myc
protein expression revealed results similar to the mRNA level
(Fig. 1C). Moreover, we found that the miR-449c expression was
inversely correlated with c-Myc mRNA and protein expression in
NSCLC specimens (Fig. 1D and E).
3.2. MiR-449c upregulation inhibits NSCLC cell proliferation and
invasion
The miR-449c deregulation suggested that miR-449c may regu-
late NSCLC cell progression. Therefore, MTT assay, invasion assay,
and ﬂow cytometry analysis were performed to validate the effect
of miR-449c on NSCLC cells, NCI-H23 and NCI-H838. The transfec-
tion of miR-449c expression plasmid could signiﬁcantly upregulate
the miR-449c expression in NCI-H23 and NCI-H838 cells (Fig. 2A).
MTT assay (Fig. 2B) and ﬂow cytometry (Fig. 2E) analysis results
indicated that miR-449c overexpression signiﬁcantly inhibited cell
viability and promoted cell apoptosis in NSCLC cells compared
with the control groups. The result of the invasion assay showed
Fig. 2. MiR-449c upregulation inhibits proliferation and promotes apoptosis of NSCLC cell lines. NCI-H23 and NCI-H838 cells were transfected with miR-449c expression
vector or control vector. (A) The expression level of miR-449c following transfection of miR-449c expression plasmid or control vector in NCI-H23 and NCI-H838 cells was
analyzed by real-time qRT-PCR. (B) MTT assay was used to detect the cell viability at 24, 48, and 72 h after transfection. (C, D and E ) NCI-H23 and NCI-H838 cells were
collected 48 h post-transfection for invasion assay (C and D) and ﬂow cytometry analysis (E). ⁄P < 0.05.
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(Fig. 2C).
3.3. MiR-449c directly targets MYC and downregulates its expression
c-Myc is a well-known oncogene in a variety of tumors. Based
on the inverse correlation between miR-449c and c-Myc expres-
sion, we hypothesized that the effect of miR-449c in NSCLC cell
may be mediated by c-Myc. To validate this hypothesis, we used
TargetScan database (Version 5.1) to determine the relationship
between miR-449c and c-Myc. As shown in Fig. 3A, c-Myc 30UTR
was found to contain a complementary region of miR-449c seed
sequence (138–144 of the c-Myc 30UTR). To test whether miR-
449c could directly repress the c-Myc expression, Western blot
and luciferase activity assay were performed. In the Western blot
assay, the c-Myc protein level was lower in the miR-449c expres-
sion plasmid-transfected NCI-H23 cells than those in control
groups (Fig. 3B). For the luciferase activity assay, luciferase repor-ter vectors carrying the 3’UTR or mutant 3’UTR of c-Myc (c-Myc
30UTR or Mut-c-Myc 30UTR) were cotransfected with miR-449c
expression plasmid or control plasmid. The results showed that
miR-449c could suppress the luciferase activity of reporter plasmid
with wild-type c-Myc 30UTR. However, miR-449c did not affect the
expression of luciferase with mutated c-Myc 30UTR (Fig. 3C).
3.4. Restoration of c-Myc counteracts the effect of miR-449c
upregulation in NSCLC cells
We have proven that c-Myc is directly targeted by miR-449c,
and the upregulation of miR-449c inhibited NSCLC cell prolifera-
tion and promoted apoptosis. These results indicated that
miR-449c regulates NSCLC cell progression by targeting c-Myc.
To further conﬁrm this mechanism, MYC CDS expression plasmid
without 30UTR was used to reverse the negative effects of miR-
449c in NSCLC cells. Transfection of c-Myc expression plasmid
changed the protein levels of c-Myc, AKT, p-AKT (ser473), and
Fig. 3. MiR-449c directly regulates c-Myc expression by binding to 30UTR. (A) Binding sequence of miR-449c in c-Myc 3’UTR predicted by Targetscan database. (B) The c-Myc
expression in NCI-H23 cells after transfection of miR-449c expression vector was tested by Western blot. Normalization was performed with GAPDH. (C) c-Myc 30UTR or
mutated c-Myc 30UTR was transfected alone or cotransfected with miR-449c expression vector or control vectors into NCI-H23 cells. After 48 h, cells were collected and
analyzed. The intensity of ﬁreﬂy luciferase in cells cotransfected with miR-449c expression vector and c-Myc 30UTR decreased compared with control group (P < 0.05).
However, miR-449c upregulation did not affect the intensity of ﬁreﬂy luciferase when cells were transfected with the mutated c-Myc 30UTR. ⁄P < 0.05.
Fig. 4. Restoration of c-Myc expression reverses the effect of miR-449c on NSCLC cell lines. (A) c-Myc expression plasmid was transfected into NCI-H23 and NCI-H838 cells
previously treated with miR-449c expression vector. After 48 h, c-Myc, P53, AKT and p-AKT(ser473) protein levels in NCI-H23 were detected by Western blot. (B and C) The
effects of c-Myc expression on cell apoptosis and invasion were evaluated by ﬂow cytometry and transwell assay. c-Myc overexpression signiﬁcantly inhibited cell apoptosis
and promoted the invasive ability of miR-449c-upregulated NSCLC cell lines. ⁄P < 0.05.
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Fig. 5. MiR-449c inhibits NSCLC tumor growth in vivo. (A) Stable cell lines of miR-449c-overexpressed NCI-H23 and NCI-H838 cells were injected subcutaneously in the nude
mice. Mice were sacriﬁced 22 d later for evaluation. Gross morphology of tumor is shown. (B) MiR-449c upregulation decreased the volume of tumors compared with the
control group. (C and D) The expression of miR-449c (C) and MYC protein level (D) in solid tumors were analyzed by real-time qRT-PCR and Western blot. U6 snRNA or
GAPDH as the control. ⁄P < 0.05.
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(Fig. 4A). Furthermore, we evaluated the effects of c-Myc on cell
apoptosis and invasion. The results suggested that c-Myc can re-
verse the effect of miR-449c on cell apoptosis and invasion in
NSCLC cells than that in control group (Figs. 4B and C).
3.5. MiR-449c inhibits tumor growth of NSCLC in vivo
To investigate the role of miR-449c in vivo, stable cell lines with
upregulated miR-449c and control group were established. Cells
were injected into mice subcutaneously. Then, 22 d after implanta-
tion, the mice were sacriﬁced, and the tumors were removed and
photographed. Tumor volume of both NSCLC cells was smaller in
the miR-449c upregulated groups than that in the control groups
(Fig. 5A and B). Meanwhile, miR-449c and c-Myc protein expres-
sion levels in the tumor tissues were analyzed by real-time qRT-
PCR and Western blot. MiR-449c expression was upregulated,
whereas the MYC expression was obviously downregulated in
the miR-449c upregulated groups (Fig. 5C and D).
4. Discussion
Several studies have shown that miRNAs are closely related to
NSCLC. MiR-34a and miR-212 are downregulated in NSCLC
[17,18], while MiR-200 suppresses lung tumorigenesis by targeting
Flt1 [19]. In gastric cancer, miR-449c inhibits cell proliferation by
activating the p53 pathway [20]. However, miR-449c was found
to be upregulated in primary pigmented nodular adrenocortical
disease and targeted WISP2 [21]. In the present study, miR-449clevels in NSCLC and normal tissues were compared. The results
indicated that the miR-449c level was lower in the NSCLC speci-
mens. MiR-449c overexpression was shown to inhibit NSCLC cell
phenotypes. In addition, miR-449c overexpression in nude mice
inhibited NSCLC tumor growth in vivo.
To discover the putative association between miR-449c and
MYC expression, luciferase reporter and Western blot assay were
performed. The results showed that miR-449c repressed MYC
expression at the protein level, and MYC was directly targeted by
miR-449c. MYC is a multifunctional gene, and deregulated MYC
activity is found in several human cancers. c-Myc overexpression
potently promotes cell growth and proliferation concomitant with
the induction of apoptosis in numerous cell types. In breast cancer,
MYC upregulates the miR-1245 expression, which then represses
BRCA2 translation [22]. MYC expression in lymphoma was shown
to contribute to EZH2 expression by repressing miR-26a [23].
Moreover, EGFR promotes lung tumorigenesis by activating MYC,
which in turn stimulates miR-7 expression [24]. In this study, we
showed that the MYC expression was upregulated and inversely
correlated with miR-449c levels in NSCLC. In addition, MYC over-
expression inhibited cell proliferation compared with that of trans-
fection control vector in miR-449c-overexpressed NSCLC cells.
Furthermore, MYC expression also resist the effect of miR-449c
and promote NSCLC tumor growth in vivo.
In summary, this study indicated the importance of miR-449c
and MYC regulation in NSCLC. We found the negative role of
miR-449c in NSCLC cell proliferation and carcinogenesis by down-
regulating the MYC expression both in vitro and in vivo. This newly
identiﬁed miR-449c/MYC link in NSCLC will be useful in the deeper
L.-J. Miao et al. / FEBS Letters 587 (2013) 1359–1365 1365understanding of NSCLC and may provide a new, potential thera-
peutic target for cancer treatment.
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